Cyclacel Pharmaceuticals Inc (CYCC)
2.27
-0.04
(-1.73%)
USD |
NASDAQ |
May 10, 16:00
2.27
0.00 (0.00%)
After-Hours: 20:00
Cyclacel Pharmaceuticals Price to Book Value: 4.930 for May 10, 2024
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| May 09, 2024 | 5.017 |
| May 08, 2024 | 5.039 |
| May 07, 2024 | 4.583 |
| May 06, 2024 | 4.496 |
| May 03, 2024 | 4.344 |
| May 02, 2024 | 5.408 |
| May 01, 2024 | 5.755 |
| April 30, 2024 | 4.604 |
| April 29, 2024 | 2.954 |
| April 26, 2024 | 3.280 |
| April 25, 2024 | 3.475 |
| April 24, 2024 | 4.995 |
| April 23, 2024 | 3.888 |
| April 22, 2024 | 3.801 |
| April 19, 2024 | 3.866 |
| April 18, 2024 | 4.018 |
| April 17, 2024 | 4.257 |
| April 16, 2024 | 3.627 |
| April 15, 2024 | 3.410 |
| April 12, 2024 | 3.822 |
| April 11, 2024 | 4.213 |
| April 10, 2024 | 4.452 |
| April 09, 2024 | 4.583 |
| April 08, 2024 | 4.583 |
| April 05, 2024 | 4.561 |
| Date | Value |
|---|---|
| April 04, 2024 | 4.762 |
| April 03, 2024 | 4.756 |
| April 02, 2024 | 4.604 |
| April 01, 2024 | 4.452 |
| March 28, 2024 | 4.582 |
| March 27, 2024 | 4.257 |
| March 26, 2024 | 4.170 |
| March 25, 2024 | 4.648 |
| March 22, 2024 | 4.752 |
| March 21, 2024 | 4.735 |
| March 20, 2024 | 4.886 |
| March 19, 2024 | 5.104 |
| March 18, 2024 | 5.451 |
| March 15, 2024 | 5.278 |
| March 14, 2024 | 5.421 |
| March 13, 2024 | 5.625 |
| March 12, 2024 | 5.388 |
| March 11, 2024 | 5.473 |
| March 08, 2024 | 5.734 |
| March 07, 2024 | 5.408 |
| March 06, 2024 | 5.147 |
| March 05, 2024 | 5.625 |
| March 04, 2024 | 5.864 |
| March 01, 2024 | 6.298 |
| February 29, 2024 | 5.560 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
0.2551
Minimum
Dec 28 2022
6.448
Maximum
Feb 16 2024
1.147
Average
0.7936
Median
Mar 05 2020
Price to Book Value Benchmarks
| Corvus Pharmaceuticals Inc | 2.605 |
| Oragenics Inc | 5.233 |
| Relmada Therapeutics Inc | 1.248 |
| Alpine Immune Sciences Inc | 12.98 |
| MAIA Biotechnology Inc | 133.62 |
Price to Book Value Related Metrics
| Price | 2.27 |
| Earnings Yield | -1.19K% |
| Market Cap | 2.993M |